China Resources Double-Crane Pharmaceutical (SHA:600062), through subsidiaries, received drug registration certificates from the National Medical Products Administration for three drugs, according to a Shanghai bourse filing on Wednesday.
The certificates are for isavuconazonium sulfate for injection, a treatment for invasive aspergillosis and invasive mucormycosis; sorbitol and mannitol irrigation solution, which is used for urological surgeries; and brexpiprazole tablets, a drug for schizophrenia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments